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Abstract
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The human organic anion-transporting polypeptides OATP1B1 (SLCO1B1) and OATP1B3
(SLCO1B3) are liver-enriched membrane transporters of major importance to hepatic uptake of
numerous endogenous compounds including bile acids, steroid conjugates, hormones, and drugs
including the 3-hydroxy-3-methylglutaryl Co-A reductase inhibitor (statin) family of cholesterollowering compounds. Despite their remarkable substrate overlap, there are notable exceptions: in
particular, the gastrointestinal peptide hormone cholecystokinin-8 (CCK-8) is a high affinity
substrate for OATP1B3 but not OATP1B1. We utilized homologous recombination of linear DNA
by E. coli to generate a library of cDNA containing monomer size chimeric OATP1B1-1B3 and
OATP1B3-1B1 transporters with randomly distributed chimeric junctions to identify three discrete
regions of the transporter involved in conferring CCK-8 transport activity. Site-directed
mutagenesis of three key residues in OATP1B1 transmembrane helices 1 and 10, and extracellular
loop 6, to the corresponding residues in OATP1B3, resulted in a gain of CCK-8 transport by
OATP1B1. The residues appear specific to CCK-8, as the mutations did not affect transport of the
shared OATP1B substrate atorvastatin or the OATP1B1-specific substrate estrone sulfate. Regions
involved in gain of CCK-8 transport by OATP1B1, when mapped to the crystal structures of
bacterial transporters from the major facilitator superfamily, suggest these regions could readily
interact with drug substrates. Accordingly, our data provide new insight into the molecular
determinants of the substrate specificity of these hepatic uptake transporters with relevance to
targeted drug design and prediction of drug-drug interactions.
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The organic anion-transporting polypeptides (OATPs; gene symbol solute carrier family
SLCO) form a superfamily of transmembrane proteins involved in the transport of a variety
of amphipathic substrates across the plasma membrane in a sodium-independent manner. To
date, over 80 members of the OATP superfamily in 13 different species have been identified
by the presence of the OATP superfamily signature D-X-RW-(I,V)-GAWW-X-G-(F,L)-L.
The two members of the human subfamily OATP1B, OATP1B1 (previously known as
OATP-C, liver-specific transporter 1 (LST-1), or OATP2; gene symbol SLCO1B1,
previously SLC21A6) and OATP1B3 (previously known as LST-2, or OATP8; gene symbol
SLCO1B3, previously SLC21A8), share 80% sequence identity1. Their expression is
predominantly observed on the basolateral membrane of hepatocytes, where they mediate
the hepatic uptake of substrates from the portal blood2–5. Not surprisingly, OATP1B1 and
OATP1B3 share a broad substrate specificity, and are capable of transporting bile salts,
steroid conjugates, the thyroid hormones T3 and T4, eicosanoids, cyclic peptides,
bromosulfophthalein, the natural toxins phalloidin and microcystin-LR as well as numerous
drugs, such as methotrexate, rifampin, and many of the 3-hydroxy-3-methylglutaryl
coenzyme A (statin) family of compounds1, 6–8.
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Reports of mice with deletion of Oatp1b2 (Slco1b2), the closest murine ortholog to
OATP1B1 and OATP1B3, observed altered pharmacokinetic profiles of prototypical
OATP1B1 substrates pravastatin and rifampin9, as well as protection from hepatotoxicity
induced by phalloidin and microcystin-LR10. The clinical relevance of OATP1B1 to hepatic
elimination is also evidenced by the profound effect of single nucleotide polymorphisms
(SNPs) on the observed pharmacokinetic profile of drug substrates7. Remarkably, a
previously identified SNP in SLCO1B1 has been shown to be the single most important
predictor of statin-induced muscle myopathy, a relatively rare but potentially fatal side effect
of statin therapy11–12.
Despite their remarkable sequence similarity and overlapping substrate specificity, there are
some notable differences in the compounds transported by OATP1B1 and OATP1B3. For
example, OATP1B3 transports the gastrointestinal peptide hormone cholecystokinin-8
(CCK-8), which is not a substrate of OATP1B11, 13–14. Conversely, OATP1B1 transports
the steroid conjugate estrone sulfate while OATP1B3 does not show appreciable transport
activity. Accordingly, the wide and overlapping but not identical substrate specificity of
OATP1B1 and OATP1B3, combined with their significant sequence homology, suggests
that there may be key sequence differences that confer isoform-specific divergence in
substrate specificity.
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Previously, transmembrane (TM) helices eight and nine were identified as important for
estrone sulfate and estradiol-17β-glucuronide transport by OATP1B115, and the mutation of
four residues in TM10, Leu545, Phe546, Leu550 and Ser554, resulted in complete loss of
estrone sulfate transport16. Conserved, positively charged amino acids in other areas of
OATP1B1 also appear to be important for estrone sulfate and estradiol-17β-glucuronide
transport17. With respect to OATP1B3, previous studies have indicated a role for TM10 in
mediating CCK-8 transport18. Similar to OATP1B1, conserved, positively charged amino
acids in OATP1B3 appear to be important for transport of sulphobromophthalein (BSP),
pravastatin and taurocholate19–20.
Given the importance of OATP1B1 in hepatic drug uptake, the molecular basis for substrate
specificity needs to be defined to more fully understand the in vivo distribution of its
substrates, and to aid in the rational design of drugs targeting the liver as their site of action.
In the present work, we employed a strategy of random chimeragenesis to obtain insight to
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specific regions involved in CCK-8 transport. Our results indicate that amino acid residues
in three distinct regions of the transporter are required to enable CCK-8 transport by
OATP1B3. Importantly, we were able to confer CCK-8 transport by OATP1B1 through
targeted mutagenesis of amino acids in the regions noted to be important for CCK-8
transport by OATP1B3.

Experimental Section
Materials
[3H]-CCK-8(L-aspartyl-L-tryosyl-L-methionylgylcyl-L-tryptophyl-L-methionyl-L-aspartylL-phenylalaninamide hydrogen sulfate ester; 93 Ci/mmol, >97% purity) was purchased from
GE Healthcare (Buckinghamshire, UK), [3H]-estrone sulfate (57.3 Ci/mmol, >97% purity)
from PerkinElmer (Boston, MA), and [3H]-atorvastatin (5 Ci/mmol, >97% purity) from
American Radiolabeled Chemicals (St Louis, MO). Unlabeled estrone sulfate was from
Sigma-Aldrich (St. Louis, MO), atorvastatin was from Toronto Research Chemicals (North
York, Canada) and cholecystokinin-8 was from Bachem Bioscience (King of Prussia, PA).
OATP1B chimera plasmid construct
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The master plasmids for chimeragenesis were created by inserting the coding sequence of
OATP1B1 into a previously described pEF6/V5-His TOPO plasmid containing
OATP1B321. Two master plasmids with the transporters in a tandem head-to-tail
arrangement were created: OATP1B1-1B3 and OATP1B3-1B1. OATP1B1 was released
from pEF612 by PCR using the Phusion® High Fidelity PCR kit (New England Biolabs,
Ipswich, MA), with primers that introduced restriction enzymes sites to allow insertion of
OATP1B1 into the multiple cloning regions of pEF6-OATP1B3. For OATP1B1-1B3,
OATP1B1 was released using the forward primer 5'-ggatccacta gtccagtgtg gtggaattgc
ccttgatatc tatatttcaa-3' and the reverse primer 5'-tctagacact agtggccgtt aacgtgctgc atatgtgcag
aattgccctt ttaacaatgt-3', with nucleotides mutated to add HpaI, NdeI and SpeI restriction sites
in bold. The resulting fragment was ligated into pEF-OATP1B3 using SpeI and the
orientation of the fragment was confirmed by restriction digest (Fig. 1A). For
OATP1B3-1B1, the forward primer 5' – gtccagtgcg gccgcattgc catttaaatc tatatttcaa
ccatggacca – 3' to add NotI and SwaI sites and reverse primer 5' – gccactgt gctggatatc
tctagaattg cccttttaac aatgtgt – 3' to add XbaI sites were used. The resulting fragment was
ligated into pEF-OATP1B3 using NotI and XbaI (Fig. 1B). The resulting master plasmids
OATP1B1-1B3 and OATP1B3-1B1 were linearized by HpaI and NdeI, and NotI and SwaI
respectively, and inserted into TOP10 Escherichia coli (Invitrogen, Carlsbad, CA).
Restriction fragments resulting from digesting the ensuing plasmids with SpeI and XbaI
were used to select those plasmids containing a monomeric OATP1B sequence. OATP1B1specific restriction enzymes were used to estimate the approximate location of the junction
between OATP1B1 and OATP1B3; sequencing determined the exact location of the
junction.
Site-directed mutagenesis
Single, double and triple point mutations were introduced into the coding sequence of pEF6OATP1B1 and pEF6-OATP1B3 using the QuikChange® Multi Site-directed Mutagenesis
kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The primers used
are summarized in SI Table 1. The presence of all mutations was confirmed by sequencing.
Transient transfection and transport assay
HeLa cells were plated in 12-well plates at 2.5 × 105 cells/well, to be transfected the next
day. Transporters were expressed using a transient heterologous expresssion system as
previously described12. Briefly, 750 ng cDNA per well as measured by PicoGreen® Assay
Mol Pharm. Author manuscript; available in PMC 2013 April 2.
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(Invitrogen) with Lipofectin® (Invitrogen) in Opti-MEM® (Lonza, Walkersville, MD).
Sixteen hours later, the cells were washed in pre-warmed Opti-MEM (CCK-8) or Krebs
Henseleit Bicarbonate (KHB) buffer (estrone sulfate and atorvastatin; 1.2 mM MgSO4, 0.96
mM KH2PO4, 4.83 mM KCl, 118 mM NaCl, 1.53 mM CaCl2, 23.8 mM NaHCO3, 12.5 mM
HEPES, 5 mM glucose, pH 7.4), then dosed with 400 μl Opti-MEM or KHB buffer
containing radiolabeled substrates and varying concentrations of unlabeled compounds, and
incubated at 37 °C. Chimeric transporters and OATP1B1 mutants screened for CCK-8
transport activity (2 nM) were incubated for 30 min. Kinetics experiments measuring uptake
by the triple mutants were conducted at 10 min, within the linear uptake phase of CCK-8 by
OATP1B3. Estrone sulfate uptake (100 nM) was measured after 5 min incubation,
atorvastatin uptake (75 nM) was measured after 10 min. Cells were washed three times in
ice-cold PBS, harvested in 500 μl 1% SDS, and radioactivity was measured by scintillation
counting. Specific uptake was determined by subtracting uptake by vector-transfected
control from the total measured. Percent OATP1B3 uptake was calculated by dividing the
specific uptake of a chimeric or mutated transporter by the specific uptake of CCK-8 by
wild-type OATP1B3 during the same experiment. Statistical determination of differences
was by analysis of variance, with Dunnett's multiple comparison test, and student's t-test as
appropriate. Kinetic parameters Km and Vmax were calculated by Michaelis-Menten nonlinear curve fitting (GraphPad Prism, San Diego, CA).
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Cell surface expression and immunoblots
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Cell surface biotinylation was carried out as previously described12 to determine the extent
of cell surface trafficking of heterologously expressed transporters. Briefly, Hela cells (~ 8 ×
105 cells/well) were transfected as described for transport experiments. Sixteen hours posttransfection, the cells were washed in ice-cold PBS-Ca2+/Mg2+ (138 mM NaCl2, 2.7mM
KCl, 1.5 mM KH2PO4, 1mM MgCl2, 0.1 mM CaCl2, pH 7.3) and treated with sulfo-Nhydroxysuccinimide-SS-biotin (Thermo Scientific, Rockford, IL). The cells were washed
with ice-cold PBS-Ca2+/Mg2+ containing 100 mM glycine and disrupted with lysis buffer
(10 nM Tris base, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, pH 7.4)
containing protease inhibitors (Complete, Roche Applied Science, Indianapolis, IN).
Following centrifugation, 140 μl of streptavidin-agarose beads (Thermo Scientific,
Rockford, IL) were added to 600 μl of cell lysate, and incubated for one hour at room
temperature. Beads were washed four times with ice-cold lysis buffer, and biotinylated
proteins released from the beads by adding Laemmli buffer. Biotinylated (cell surfaceexpressed) fractions and total cell lysates (25μl) were subjected to Western blotting analysis
for detection of OATP1B1 or OATP1B3 by specific polyclonal antibodies as previously
described12. The intracellular, endoplasmic reticulum-resident protein calnexin was probed
as a loading control (1:2000 dilution, StressGen,Victoria, British Columbia, Canada).
Densitometry analysis was performed using ImageJ (http://imagej.nih.gov/ij/).

Results
[3H]-CCK-8 uptake by transfected cells expressing OATP1B1-1B3 and OATP1B3-1B1
chimeras identifies regions in TM1, TM10 and extracellular loop 6 (ECL6) involved in
CCK-8 transport
A library of OATP1B1-1B3 and OATP1B3-1B1 chimeric expression constructs was
generated using homologous recombination of linear DNA by E. coli. Sequencing of the
constructs indicated that the chimeric junctions were well distributed throughout the coding
sequence (Fig. 2). Screening of the chimeras for transport of CCK-8 identified three regions
of interest defined by the overlap of sequences causing altered transport activity in both sets
of chimeras. A substantial decrease in CCK-8 transport by OATP1B1-1B3 chimeras with
junctions at Gly26 and Phe59 combined with a modest increase by OATP1B3-1B1 chimeras
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with junctions at Ser35 and Cys101 forms a region of interest between Ser35 and Phe59. This
region is located close to the predicted extracellular boundary of transmembrane helix 1
(TM1). A second region of interest is formed by a change in transport activity in
OATP1B1-1B3 chimeras with junctions at Phe534 and Asp596, and OATP1B3-1B1 chimeras
with junctions at Tyr481 and Lys568, creating a region of interest between Phe534 and Lys568.
A third region is formed by the overlap of a region responsible for a significant gain in
OATP1B3-1B1 transport in chimeras with junctions at Gly608 and Gln652 with a small but
detectable decrease in CCK-8 transport in OATP1B1-1B3 chimeras with junctions at Asp596
and Ser629. This region, defined by Gly608 and Ser629, is located in a portion of the predicted
extracellular loop (ECL) 6 close to TM12. Within these regions, seven non-conserved amino
acids in both TM1 and ECL6 and twelve non-conserved residues in TM10 were mutated in
OATP1B1 to the corresponding residue in OATP1B3.
Site-directed mutagenesis of non-conserved residues indicates amino acids at positions
45 in TM1, 545 in TM10 and 615 in ECL 6 near TM12 contribute to CCK-8 transport
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OATP1B1 mutants of nonconserved residues in OATP1B3 located in the region of TM1
defined by the chimeras were created by site-directed mutagenesis and screened for CCK-8
transport (Fig. 3). Of the seven mutants created, L36F, F38Y, T42A, A45G, S50I, I53T and
H54Q, the OATP1B1 mutant A45G showed the greatest transport activity, at 0.8% of
wildtype OATP1B3 CCK-8 transport, compared with 0.3% activity normally observed for
wildtype OATP1B1 (Fig. 3B; p < 0.01). The corresponding mutation of OATP1B3 to the
OATP1B1 residue, OATP1B3 G45A, exhibited approximately a 35% decrease in CCK-8
transport compared to wildtype OATP1B3 (Fig. 3E; p < 0.001).
In the region of TM10 defined by the chimeric transporters, a total of 12 OATP1B1 mutants
were created: Y535F, F536I, F537Y, L543I, L545S, F546L, L550T, S554T, H555F, V556I,
M557L, and I559T (Fig. 3D). Of the mutations in this region, OATP1B1 L545S exhibited
the highest level of CCK-8 transport, at 0.8% of wildtype OATP1B3 (p < 0.01).
Approximately 16% of wild CCK-8 transport was observed by the corresponding mutation
OATP1B3 S545L (Fig. 3E; p < 0.001).
Finally, of seven OATP1B1 mutants in ECL6, T609A, R610Q, S612A, T615I, T619V,
S620F and S622G, the OATP1B1 mutant T615I exhibited the greatest increase in CCK-8
transport over wildtype OATP1B1 transport, to 1.5% of OATP1B3 transport activity (p <
0.001). The corresponding mutation, OATP1B3 I615T, showed a close to 55% decrease in
transport activity (Fig. 3E; p < 0.001).
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To investigate the potential for interactions between two or more regions identified by the
chimeric transporters to be involved in CCK-8 transport, the double mutants OATP1B1
A45G/L545S, OATP1B1 L545S/T615I, and OATP1B1 A45G/T615I were constructed. The
double mutants exhibited 3.9, 2.2 and 2.9 % of OATP1B3 CCK-8 uptake, respectively (Fig.
5A). Similarly, the double mutants OATP1B3 G45A/S545L, OATP1B3 S545L/I615T and
OATP1B3 G45A/I615T exhibited a marked, but not total, loss of CCK-8 transport activity
(Fig. 5C).
In contrast, when a mutation from each of the three regions identified by the chimeric
transporters were combined in the triple mutant OATP1B1 A45G/L545S/T615I, a profound
gain of CCK-8 transport activity was observed, corresponding to 16% of wildtype
OATP1B3 CCK-8 uptake (Fig. 5B; p < 0.001). The corresponding triple mutant OATP1B3
G45A/S545L/I615T exhibited almost complete abrogation of CCK-8 transport (Fig. 5D; p <
0.001).
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Cell surface biotinylation studies were conducted to examine whether the observed changes
in transport activity were related to cell surface expression of the transporter. Western blot
analysis indicates that there is no significant difference in cell surface expression in those
OATP1B1 mutants with altered CCK-8 transport activity (Fig. 4A, 4C), suggesting that the
increase in CCK-8 transport activity observed is due to altered substrate recognition or
transport capacity, and does not appear to be a result of changed levels of cell surface
expressed transporter. On the other hand, reduced cell surface expression of OATP1B3
G45A/S545L/I615T may partially account for the loss of CCK-8 transport, though it is
important to note that the mutant cell surface expression is approximately 40% of wildtype,
suggesting that the protein is not capable of CCK-8 transport (Fig 4D).
Characterization of CCK-8 transport kinetics of OATP1B1 triple mutant and wildtype
OATP1B3
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The kinetics of CCK-8 uptake by the OATP1B1 triple mutant A45G/L545S/T615I
compared to wildtype OATP1B3 were examined by measuring [3H]-CCK-8 uptake after 10
minutes in the presence of unlabeled CCK-8 varying in concentration from 2 nM to 100 μM.
Results indicate a higher Km (15.4 ± 4.2 μM vs. 6.5 ± 2.0 μM) and a lower Vmax (0.020 ±
0.0018 nmol/mg protein/min vs. 0.064 ± 0.0049 nmol/mg protein/min) for the OATP1B1
triple mutant compared to wildtype OATP1B3 uptake (Fig. 6). Vmax and Km for the
OATP1B1-mediated uptake of CCK-8 were undeterminable. Intrinsic clearance values
(Vmax/Km) were lower in the OATP1B1 triple mutant (1.2 μl/mg protein/min) compared to
wildtype OATP1B3 (9.8 μl/mg protein/min), due to the lower Vmax and higher Km of the
OATP1B1 triple mutant.
Transport of other OATP1B substrates by OATP1B1 and OATP1B3 triple mutants
The OATP1B1-specific substrate estrone sulfate was not transported by wildtype OATP1B3
or the OATP1B3 triple mutant G45A/S545L/I615T (Fig. 7A). Transport of estrone sulfate
by the OATP1B1 triple mutant A45G/L545S/T615I was reduced to approximately 50% of
uptake by wildtype OATP1B1. Transport of the shared OATP1B substrate atorvastatin was
modestly increased by OATP1B1 A45G/L545S/T615I and modestly reduced by OATP1B3
G45A/S545L/I615T, compared to their respective wildtype transporters (Fig. 7B,C).

Discussion
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The molecular basis for the substrate specificity and transport activity of the OATP
superfamily is not well understood, despite that OATP transporters are increasingly
recognized as important determinants of interindividual variation in response to many drugs
in clinical use7. Transport by the OATPs appears to be mediated by a Na+-independent and
electroneutral process, but the precise details of the transport mechanism, including the
identity of the counterion, remain to be elucidated. Hydropathy analysis of OATP/Oatp
sequences indicates that members of the superfamily form 12 TMs with intracellular aminoand carboxy termini, an arrangement that was shown experimentally for the murine
transporter oatp1a122. The OATPs have in common a large predicted ECL5 between TMs 9
and 10; characterization of conserved cysteine residues in ECL5 of OATP2B1 indicate these
residues are involved in membrane trafficking and transport function23. Other conserved
features include N-glycosylation sites in ECLs 2 and 5, and the superfamily signature that
designates the OATP family, found at the border between ECL3 and TM624.
CCK-8 is a gastrointestinal peptide hormone released postprandially in response to nutrients
in the gut, and is involved in delaying gastric emptying, as well as stimulating pancreatic
enzyme secretion, gall bladder contraction and intestinal motility25. Interestingly, CCK-8
appears to be transported by OATP1B3 but not by the closely related OATP1B1. The main
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goal of our current study was to identify key regions or amino acid residues which could
confer gain of CCK-8 transport function for OATP1B1.
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We first noted that chimeras from each set sharing the same junction close to middle of
transporter (Val339), OATP1B3-1B1-6, and OATP1B1-1B3-9, demonstrated a modest gain
or significant loss of wildtype OATP1B3 CCK-8 transport, respectively, compared to
adjacent chimeras (Fig. 2). OATP1B1-1B3-9 demonstrated higher CCK-8 transport activity
than OATP1B3-1B1-6 (Fig. 2), consistent with other reports that the C-terminal portion of
OATP1B3 is more important for CCK-8 transport than the N-terminal portion18. Systematic
comparison of the individual chimeric transporter function suggested that amino acids in
TM1, TM10, and ECL6 may be important for CCK-8 transport. Given the two negatively
charged aspartic acid residues in CCK-8, it might be expected that there exists some critical
interaction with positively charged residues in the transporter, especially given the
importance of positively charged residues to OATP1B3 transport of other substrates19–20.
However, none of the OATP1B1 mutations made were to a positively charged residue in
OATP1B3. Three nonconserved positively charged residues in OATP1B1 were substituted
for an uncharged residue at the corresponding position in OATP1B3, however, none of the
three variants, H54Q, H555F or R610Q, showed any significant increase in CCK-8 transport
(Fig. 3B, 3C and 3D). In total five aromatic residues, Phe38, Tyr535, Phe536, Phe537 and
Phe546 in OATP1B1 fell within the regions identified, and were mutated to the
corresponding residue in OATP1B3. At three of these positions, the mutation was a semiconserved mutation to a different aromatic residue (F38Y, Y535F and F537Y). In three
other positions, non-aromatic residues in OATP1B1 were converted to aromatic side chains:
L36F, H555F and S620F. The absence of any significant gain of function in any of these
OATP1B1 mutations suggests that these residues may not be involved in the CCK-8
transport cycle.
The mutation of an alanine at position 45 to glycine in TM1 of OATP1B1 resulted in an
increase in CCK-8 transport. It is possible this may be attributed to the loss of bulk of the
methyl group difference between these two side chains, a consideration particularly given
that CCK-8 is a relatively large substrate. Mutation of OATP1B1 from a leucine to a serine
at position 545 adds a hydroxyl group, in addition to reducing the bulk associated with the
side chain, while the mutation of threonine at position 615 to isoleucine results in a loss of a
hydroxyl group. This suggests a possible role for the interaction of a hydroxyl group with
CCK-8 in a way that either promotes or prevents CCK-8 transport. It is also possible that the
mutations noted alter protein conformation in a way that affects substrate specificity without
directly interacting with CCK-8.
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A previous report that utilized a TM domain swapping strategy indicated the importance of
TM10 in CCK-8 transport by OATP1B318. It should be noted that the study by Gui and
Hagenbuch focused on the substitution of individual transmembrane spanning domains in
OATP1B3 with the corresponding TMs of OATP1B1. Accordingly, their study was
designed to detect a loss of CCK-8 transport due to the presence of an OATP1B1-specific
TM region. In the current study, we pursued a chimeragenesis approach to generate a library
of both OATP1B1-1B3 and OATP1B3-1B1 monomer sized chimeras to identify chimeric
junctions that revealed a gain and corresponding loss of function, without an a priori bias
regarding the overall importance of TM regions versus intracellular or extracellular loops in
the transporter. Although our data confirms TM10 is a key region for CCK-8 interaction,
mutation of a single residue in TM10 is not sufficient to impart a true gain of OATP1B1mediated CCK-8 transport (Fig. 3D). Indeed our current data reveals that the synergistic
interaction with two additional domains is essential. Although it should be noted that the
overall activity of the OATP1B1 45/545/615 triple mutant was lower than that of the
wildtype OATP1B3, it is remarkable that three targeted amino acid substitutions changed
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OATP1B1 from complete inability to transport CCK-8 to attaining near 15% of OATP1B3
activity (Fig. 5B). Conversely, substitution of amino acids at those positions in OATP1B3 to
the corresponding residue in OATP1B1 resulted in the near complete loss of OATP1B3mediated CCK-8 uptake (Fig. 5D), despite the fact this mutant is expressed on the cell
surface, albeit at lower levels than wildtype OATP1B3 (Fig. 4D).
The three key amino acid residues noted for CCK-8 gain of substrate specificity do not
appear to confer the opposite effect, that is, OATP1B3 gain of function for an OATP1B1specific substrate such as estrone sulfate (Fig. 7A). Similarly, there was not a readily
discernible effect of the three amino acid residues on the transport of the shared (OATP1B1
and OATP1B3) substrate and commonly prescribed statin, atorvastatin (Fig. 7B,C).
Therefore it seems the amino acids we have identified in this study, though key residues
with respect to CCK-8 transport, are not essential to conferring OATP1B1-specific or
OATP1B1 and 1B3 shared substrate specificity. This is consistent with a recent report that
TM8 and TM9 of OATP1B1 are involved in the transport of its steroid conjugate substrates
estrone sulfate and estradiol glucuronide15.
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Like other transporters, little structural data for the OATPs exists due to challenges
associated with the purification and crystallization of large membrane-bound structures. A
homology model for OATP1B3 based on the crystal structures of the glycerol-3-phosphate
transporter and lactose permease from E. coli has been reported26–28. More recently, the
structure of the multidrug transporter EmrD from E. coli has been used to model
OATP1B318, 29. There appears to be significant structural conservation in the major
facilitator superfamily (MFS) of transporters30, so these crystal structures from bacteria may
serve as models to interpret data arising from functional characterization of the distantly
related OATPs. In each of the three MFS structures mentioned it appears that both TM1 and
TM10 partially form the pore of the transporter, consistent with the biochemical data
presented here to suggest that these regions are involved in CCK-8 transport (Fig. 8).
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This study is important to the drug development process for a number of reasons. The
exclusive expression of OATP1B1 on the basolateral membrane of hepatocytes makes it an
attractive target for drugs requiring entry into the liver in order to exert their effect. Species
differences in OATP expression in the liver and other organs adds complexity to studying
human OATPs and mean that in vitro and in silico approaches may prove useful in
predicting the in vivo activity of human OATPs. In addition to species differences in
substrate specificity, there are zonal differences in OATP expression within a given tissue.
In particular, OATP1B1 is expressed in hepatocytes throughout the liver, while OATP1B3 is
expressed primarily in the perivenous hepatocytes, indicating there are important differences
in transporter regulation31. Thus targeting one OATP over another has the potential to result
in even greater tissue specificity.
Finally, given the importance of OATPs to the cellular uptake of many drugs, it will be
useful to have the ability to predict the functional effect of novel polymorphisms in OATPs
that will be discovered as whole genome sequencing expands into clinical applications. At
the time of this writing, there was only one reported case of a naturally occurring
polymorphism in any of the same positions as the 26 mutations in OATP1B1 presented here,
Leu543Trp (rs72661137). It remains difficult to predict the precise effect of a polymorphism
in OATP1B1, however, there was a modest increase in CCK-8 transport by the Leu543Ile
mutant in our study (Fig 3D). Given this, combined with its proximity to the Leu545 residue
identified here to be important for CCK-8 transport, we believe it is not unreasonable to
expect that Leu543 polymorphisms may alter OATP1B1 function, and further studies of this
polymorphism may be warranted.
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In conclusion, hepatic uptake transporters are increasingly recognized as important
determinants of drug disposition and response. Accordingly, substrate recognition by
OATP1B1 and OATP1B3 may be an important consideration for predicting potential
transporter mediated drug interactions and rational drug design. Indeed substrate specificity
of OATP1B1 and OATP1B3 may also provide valuable information for enhancing liver-toplasma ratio in the design of compounds targeted to the liver. This report is the first to
identify three amino acids, 45 (TM1), 545 (TM10) and 615 (ECL6) in distinct regions of the
transporter interact to confer gain of function of transport of CCK-8 by OATP1B1. This data
contributes new insight to our understanding of substrate specificity in these important
hepatic transporters.
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Figure 1. Cloning strategy for OATP1B chimeragenesis

(A) The expression plasmid pEFOATP1B1-1B3 was created by ligating cDNA coding for
OATP1B1 into pEF6-OATP1B3 at the SpeI restriction site. The unique restriction sites NdeI
and HpaI allow for linearization of the plasmid prior to transformation and homologous
recombination in E. coli. (B) The expression plasmid pEF-OATP1B3-1B1 was created by
ligating OATP1B1 into pEF6-OATP1B3 between NotI and XbaI restriction sites in the
multiple cloning region. The unique restriction sites NotI and SwaI allow for linearization of
the plasmid prior to transformation and homologous recombination in E. coli.
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Figure 2. Identification of regions involved in CCK-8 transport
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OATP1B1-1B3 and OATP1B3-1B1 chimeric constructs were generated by random
chimeragenesis, and sequencing determined the exact location of the junction as indicated.
In total, 16 OATP1B1-1B3 chimeras and 18 OATP1B3-1B1 chimeras were expressed in
HeLa cells and assayed for CCK-8 transport activity. Regions of interest in TM1 (hatched
line), TM10 (solid line) and ECL6 (dotted) formed by overlap of regions exhibiting changes
in [3H]-CCK-8 transport in both sets of chimeras were identified for further investigation by
site-directed mutagenesis. Values are expressed as means ± SEM of n = 5 from at least two
independent experiments.
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Figure 3. Uptake of [3H]-CCK-8 by cells expressing OATP1B1 and OATP1B3 mutants

(A) Schematic of OATP1B1, including positions of residues mutated in this study.
OATP1B1 topology is as predicted by TMPred32. Uptake of [3H]-CCK-8 by cells
transfected with OATP1B1 mutants in TM1 (B), ECL6 (C), TM10 (D) and OATP1B3
mutants (E) is expressed as % of wildtype OATP1B3 uptake ± SEM, n=4 from two
independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 relative to wildtype
OATP1B1 (B–D) and OATP1B3 (E). Amino acid sequence alignment of OATP1B1 and
OATP1B3 in regions of TM1, ECL6 and TM10 formed by overlapping areas of interest as
identified by [3H]-CCK-8 uptake by the chimeras.
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Figure 4. Immunoblot of biotinylated fractions of OATP1B1 and OATP1B3 mutants

Total protein lysates (biotinylated and nonbiotinylated fractions) from Hela cells transfected
with OATP1B1 (A) or OATP1B3 (B) mutants were subjected to SDS-PAGE, transferred to
nitrocellulose and blotted with anti-OATP1B1 or anti-OATP1B3 antibody, respectively.
Cell surface lysates (biotinylated fractions) from Hela cells transfected with OATP1B1 (C)
or OATP1B3 (D) were similarly probed.
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Figure 5. Uptake of [3H]-CCK-8 by cells expressing OATP1B1 double (A) and triple (B)
mutants, and OATP1B3 double (C) and triple (D) mutants

Values are expressed as mean % of OATP1B3 wildtype uptake ± SEM, n=4–5 from two
independent experiments. ** p < 0.01, *** p < 0.001 relative to wildtype OATP1B1 (A,B)
and OATP1B3 (C,D).
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Figure 6. Concentration-dependent uptake of CCK-8 by Hela cells transfected with wildtype
OATP1B3 and OATP1B1 A45G/L545S/T615I

Values are expressed as means ± SEM, n = 4 from two independent experiments . Kinetic
parameters were obtained by non-linear curve fitting.
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Figure 7. Transport of other OATP1B substrates

(A) Uptake of estrone sulfate by OATP1B1, OATP1B1 A45G/L545S/T615I, OATP1B3 and
OATP1B3 G45A/S545L/I615T (B) Uptake of atorvastatin by OATP1B1,OATP1B1 A45G/
L545S/T615I, OATP1B3 and OATP1B3 G45A/S545L/I615T. Values are expressed as
means ± SEM, n=4 from two independent experiments. * p < 0.05 compared to wildtype
OATP1B1.
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Figure 8. Regions involved in CCK-8 transport by OATP1B1 and OATP1B3, mapped to the
crystal structure of the multidrug resistance protein EmrD from E. coli29
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Similar results were obtained for other bacterial protein structures of the major facilitator
superfamily, the glycerol-3-phosphate transporter and lactose permease from E. coli 28.
Coordinates for the crystal structures were obtained from the Protein Data Bank
(www.pdb.org; PDB IDs 2GFP, 1PW4 and 1PV6 respectively). Sequences were aligned
using ClustalW with default settings and manually optimized with respect to secondary
structure as predicted by TMPred 32. Figure images were created in Pymol
(www.pymol.org).
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